An analytical study reported by Guren et al. at Oslo University Hospital, Norway, showed that recourse radiotherapy after local recurrence of rectal cancer may improve radical surgical resection rates and prolong survival; or may provide symptomatic relief for palliative care patients. The use of hyper-segmentation and simultaneous radiotherapy can reduce long-term adverse effects. Radiotherapy is an important part of the multidisciplinary treatment process for patients with primary rectal cancer. However, for patients with local recurrence, whether recourse radiotherapy can improve resection rates and prognosis, the investigators searched Medline, Embase and Cochrane databases and found a total of 353 literature with relevant titles or abstracts, including 10 literature describing a total of 7 prospective or retrospective studies of 375 rectal cancer patients treated with recourse radiotherapy included in this study analysis . The results showed that the median dose of initial radiotherapy in these patients was 50.4 Gy and the median time to recourse was 8 to 30 months. Most of the recourse radiotherapy was delivered by hyper-segmentation (1.2-1.5 Gy, 2 times/day) or 1.8 Gy, 1 time/day of simultaneous radiotherapy. The target area was 2-4 cm of GTV outgrowth, and the median total dose was 30-40 Gy. The median survival of patients undergoing surgical resection after recourse radiotherapy was 39-60 months, while the median survival of patients undergoing palliative treatment after radiotherapy was 12-16 months. 82-100% of patients had significant symptomatic relief. The incidence of acute toxic reactions such as diarrhea ranged from 9% to 20%, and no detailed reports of distant adverse effects were available.